FIIs bought 8,24,432 shares in this debt-free stock under Rs 50; Up over 500% from its 52-week low!

Kiran DSIJCategories: Multibaggers, Trendingjoin us on whatsappfollow us on googleprefered on google

FIIs bought 8,24,432 shares in this debt-free stock under Rs 50; Up over 500% from its 52-week low!

As of September 2025, the company is debt-free and the stock traded at a triple-digit ROE of 644 per cent with a PE of 130x.

On Monday, shares of Take Solutions Ltd gained 1 per cent to Rs 42.99 per share from its previous closing of Rs 42.59 per share. The stock has given multibagger returns of 561 per cent from its 52-week low of Rs 6.70 per share.

Incorporated in 2000, TAKE Solutions Ltd is a technology-driven company primarily focused on the Life Sciences and Supply Chain Management sectors. Its core business centres on providing comprehensive services for clinical development, including managing clinical trials, offering generics support such as bio-availability and bioequivalent studies, and handling critical regulatory functions like regulatory filing and pharmacovigilance. While providing end-to-end services in Life Sciences, the company also offers specific offerings in supply chain management, utilising an Intellectual Property-led approach to help clients optimise their supply chain processes, automate operations, and ensure compliance. This specialised focus positions TAKE Solutions as a domain-intensive service provider in its key markets.

Hunt for the next peak performer! DSIJ's Multibagger Pick identifies high-risk, high-reward stocks with potential to triple BSE 500 returns in 3–5 years. Download Service Note

TAKE Solutions has also announced a strategic roadmap to develop an advanced AI-driven diagnostic and preventive care platform, targeting India’s projected USD 197 billion preventive healthcare market by 2030. Aligned with SEBI Regulation 30 disclosures, this initiative marks a major shift from reactive treatment to predictive intelligence, leveraging India’s massive digital adoption and the rising prevalence of lifestyle-related chronic conditions. The platform aims to serve as a core technology enabler, providing doctors with AI-assisted clinical decision tools and offering consumers personalised, early-detection health insights to make affordable health intelligence accessible across the country.

The company has a market cap of over Rs 600 crore and has delivered good profit growth of 38.1 per cent CAGR over the last 5 years. In FY25, the company reported a total income of Rs 10.22 crore and a net profit of Rs 37.48 crore. As of September 2025, the company is debt-free and the stock traded at a triple-digit ROE of 644 per cent with a PE of 130x. In December 2025, FIIs took a fresh entry and bought 8,24,432 shares or 0.56 per cent stake in this debt-free stock.

Disclaimer: The article is for informational purposes only and not investment advice.